乐观
$17.89
情景价格
$8.670
-1.015 (-11.71%)收盘时
OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.
OptimizeRx Corp (OPRX) is a good buy right now, trading at $9.41 with a forward P/E of 6.91, which indicates strong potential for growth relative to its earnings. The RSI is at 69.86, suggesting that the stock is nearing overbought territory but still has room for further gains. The recent partnership with PulsePoint and the integration with OpenPath are expected to enhance revenue opportunities, positioning the company for recovery after a significant decline of 49.89% over the past year. However, the main risk is the current year-to-date change of -24.24%, indicating ongoing volatility and uncertainty in the market.
B. Riley
$11
2026-09-29
B. Riley
2026-09-29
目标价
$11
Stifel
$12
2026-08-13
Stifel
2026-08-13
目标价
$12
B. Riley
$10
2026-05-13
B. Riley
2026-05-13
目标价
$10
Lake Street
$11
2026-05-13
Lake Street
2026-05-13
目标价
$11
Stifel
$14
2026-05-13
Stifel
2026-05-13
目标价
$14
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

OptimizeRx to Hold Q3 Earnings Call on November 11, 2026

OptimizeRx Partners with PulsePoint to Enhance HCP Marketing

OptimizeRx Integrates with OpenPath to Enhance Advertising Access

OptimizeRx Appoints Troy Sarich as Advisor to Enhance Healthcare Solutions

OptimizeRx Reports Q2 Earnings Amid Strategic Transition
OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).
OptimizeRx Corp (OPRX) is a good buy right now, trading at $9.41 with a forward P/E of 6.91, which indicates strong potential for growth relative to its earnings. The RSI is at 69.86, suggesting that the stock is nearing overbought territory but still has room for further gains. The recent partnership with PulsePoint and the integration with OpenPath are expected to enhance revenue opportunities, positioning the company for recovery after a significant decline of 49.89% over the past year. However, the main risk is the current year-to-date change of -24.24%, indicating ongoing volatility and uncertainty in the market.
1 analysts cover OPRX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 24.33.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。